Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Historically, the company has been releasing figures that are above expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Weaknesses
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
AMGEN INC.-7.74%130 826
JOHNSON & JOHNSON-0.90%380 857
ROCHE HOLDING AG9.63%302 928
PFIZER, INC.-4.31%208 251
MERCK & CO., INC.-15.05%195 012
NOVARTIS AG-10.47%187 475
ABBVIE INC.2.45%159 862
NOVO NORDISK A/S12.63%149 703
ASTRAZENECA PLC14.00%140 480
BRISTOL-MYERS SQUIBB COMPAN..-6.03%136 485
ELI LILLY AND COMPANY12.58%134 118
SANOFI SA-3.45%119 078
GLAXOSMITHKLINE PLC-7.34%101 269
CHUGAI PHARMACEUTICAL CO., ..47.67%75 734
BAYER AG-15.71%66 232
ALLERGAN PLC0.97%63 659
More Results
Financials (USD)
Sales 2020 25 316 M
EBIT 2020 11 986 M
Net income 2020 7 302 M
Debt 2020 23 293 M
Yield 2020 2,82%
P/E ratio 2020 17,7x
P/E ratio 2021 15,6x
EV / Sales2020 6,09x
EV / Sales2021 5,74x
Capitalization 131 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes